











Amendment to the Claims. Please cancel claims 9-16 and 22-29 without prejudice, amend claim 17 and add new claims 30 and 31 as follows.









Listing of the claims. This listing replaces any previous listing of the claims in the instant application.







1 (Cancelled).


2 (Previously presented). A method for treating familial benign hypocalciuric hypercalcemia, neonatal severe primary hyperparathyroidism, renal secondary hyperparathyroidism, osteoporosis, malignancy-associated hypercalcemia or humoral hypercalcemia of malignancy, in a subject, comprising administering, to the subject, a compound represented by a structural formula selected from the group consisting of:














(-) - enantiomer




(+) - enantiomer




(-) - enantiomer











(+) - enantiomer


















(-) - enantiomer



















(-) - enantiomer






























; and



3 (Previously presented). A method for treating familial benign hypocalciuric hypercalcemia, neonatal severe primary hyperparathyroidism, renal secondary hyperparathyroidism, osteoporosis, malignancy-associated hypercalcemia or humoral hypercalcemia of malignancy, in a subject, comprising administering, to the subject, a compound represented by the following structural formula:



4 (Cancelled).

5 (Cancelled).

6 (Previously presented). The method of claim 2 wherein the subject is a human, a dog or a cat.



7 (Previously presented). The method of claim 2 wherein the compound is administered in combination with a pharmaceutically acceptable carrier in a pharmaceutical composition.

8 (Original). The method of claim 7 wherein the pharmaceutical composition is in the form of a pill, tablet or capsule.

9-16 (Cancelled).

17 (Currently amended). The method of claim 2 wherein ~~the the~~ level of Ca^{2+} level, parathyroid hormone level or parathyroid hormone related protein level in serum of said subject decreases following said administration.

18 (Previously presented). A method for treating familial benign hypocalciuric hypercalcemia, neonatal severe primary hyperparathyroidism, renal secondary hyperparathyroidism, osteoporosis, malignancy-associated hypercalcemia or humoral hypercalcemia of malignancy, in a subject, comprising administering, to the subject, a compound represented by the following structural formula:



19 (Previously presented). The method of claim 3 wherein the subject is a human, a dog or a cat.

20 (Previously presented). The method of claim 3 wherein the compound represented by structural formula 1 is administered in combination with a pharmaceutically acceptable carrier in a pharmaceutical composition.

21 (Previously presented). The method of claim 20 wherein the pharmaceutical composition is in the form of a pill, tablet or capsule.

22-29 (Cancelled).

30 (New). The method of claim 6 wherein the subject is a human.

31 (New). The method of claim 19 wherein the subject is a human.